activebiopharma corp

Urea,N-[4-(3-amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)-;N-[4-(3-Amino-1H-indazol-4-yl)phenyl]-N′-(2-fluoro-5-methylphenyl)urea;ABT 869;Linifanib;Linigfanib;RG 3635;AL 39324;1-[4-(3-Amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea;1148026-94-1

Urea,N-[5-(1,1-dimethylethyl)-3-isoxazolyl]-N′-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]-;N-[5-(1,1-Dimethylethyl)-3-isoxazolyl]-N′-[4-[7-[2-(4-morpholinyl)ethoxy]imidazo[2,1-b]benzothiazol-2-yl]phenyl]urea;N-(5-tert-Butylisoxazol-3-yl)-N′-[4-[7-[2-(morpholin-4-yl)ethoxy]imidazo[2,1-b][1,3]benzothiazol-2-yl]phenyl]urea;Quizartinib;AC 220;AC 010220

2-Butenamide,N-[4-[(3-chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-;N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide;915958-11-1

ALK5 INHIBITOR I;2-(3-(6-METHYLPYRIDIN-2-YL)-1H-PYRAZOL-4-YL)-1,5-NAPHTHYRIDINE;TGF-BETA RI KINASE INHIBITOR II;TRANSFORMING GROWTH FACTOR-BETA TYPE I RECEPTOR KINASE INHIBITOR I;2-(3-(6-Methylpyridine-2-yl)-1H-pyrazol-4-yl)-1,5-naphthyridine;SJN 2511;2-[3-(6-Methyl-2-pyridinyl)-1H-pyrazol-4-yl]-1,5-naphthyridine;RepSox

3-(1-Cyano-1-methylethyl)-N-[3-[(3,4-dihydro-3-methyl-4-oxo-6-quinazolinyl)amino]-4-methylphenyl]benzamide;AZ-628;AZ628/AZ-628;3-(2-Cyanopropan-2-yl)-N-(4-methyl-3-((3-methyl-4-oxo-3,4-dihydroquinazolin-6-yl)amino)phenyl)ben;AZD628;3-(2-cyanopropan-2-yl)-N-(4-methyl-3-(3-methyl-4-oxo-3,4-dihydroquinazolin-6-ylamino)phenyl)benzamide;AZ628, >=99%;Benzamide, 3-(1-cyano-1-methylethyl)-N-[3-[(3,4-dihydro-3-methyl-4-oxo-6-quinazolinyl)amino]-4-methylphenyl]-

BI-D1870;2-[(3,5-difluoro-4-hydroxyphenyl)aMino]-5,7-diMethyl-8-(3-Methylbutyl)-5,6,7,8-tetrahydropteridin-6-one;6(5H)-Pteridinone, 2-[(3,5-difluoro-4-hydroxyphenyl)amino]-7,8-dihydro-5,7-dimethyl-8-(3-methylbutyl)-;2-[(3,5-DIFLUORO-4-HYDROXYPHENYL)AMINO]-7,8-DIHYDRO-5,7-DIMETHYL-8-(3-METHYLBUTYL)-6(5H)-PTERIDINONE

Carbamic acid,N-ethyl-,1-(6,7-dimethoxy-1-phthalazinyl)-4-piperidinyl ester;Carbamic acid,ethyl-,1-(6,7-dimethoxy-1-phthalazinyl)-4-piperidinyl ester;Carbazeran;UK 31557;1-(6,7-Dimethoxyphthalazin-1-yl)piperidin-4-yl ethylcarbamate

3-Pyridinecarbonitrile,6-[[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-;3-Pyridinecarbonitrile,6-[[2-[[4-(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-;6-[[2-[[4-(2,4-Dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile;CHIR 99021;CT 99021;CHIR 911;CIHR 99021;CHIR 99201;GSK 3 inhibitor XVI;GSK 3IXV;Laduviglusib;1485056-50-5

4-Morpholineethanol,3-(4-propylheptyl)-;3-(4-Propylheptyl)-4-morpholineethanol;Delmopinol;Decapinol;(±)-Delmopinol;M 1650;3-(4-Propylheptyl)-4-(2-hydroxyethyl)morpholine;2-[3-(4-Propylheptyl)morpholin-4-yl]ethanol;143966-12-5

1H-Pyrido[4,3-b]indole,2,3,4,5-tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridinyl)ethyl]-;1H-Pyrido[4,3-b]indole,2,3,4,5-tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridyl)ethyl]-;2,3,4,5-Tetrahydro-2,8-dimethyl-5-[2-(6-methyl-3-pyridinyl)ethyl]-1H-pyrido[4,3-b]indole;Dimeboline;Preparation 84;Dimebolin;Dimebone;Dimebon;2,3,4,5-Tetrahydro-2,8-dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-1H-pyrido[4,3-b]indole;Latrepirdine;2,8-Dimethyl-5-[2-(6-methylpyridin-3-yl)ethyl]-3,4-dihydro-1H-pyrido[4,3-b]indole;2,8-Dimethyl-5-[2-(6-methyl-pyridin-3-yl)-ethyl]-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole;12687-54-6;20684-30-4

5-Pyrimidineethanethioamide,2-butyl-1,6-dihydro-N,N,4-trimethyl-6-oxo-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-;5-Pyrimidineethanethioamide,2-butyl-1,6-dihydro-N,N,4-trimethyl-6-oxo-1-[[2′-(1H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-;2-Butyl-1,6-dihydro-N,N,4-trimethyl-6-oxo-1-[[2′-(2H-tetrazol-5-yl)[1,1′-biphenyl]-4-yl]methyl]-5-pyrimidineethanethioamide;2-n-Butyl-5-dimethylaminothiocarbonylmethyl-6-methyl-3-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]pyrimidin-4(3H)-one;Fimasartan;Kanarb;2-[2-Butyl-4-methyl-6-oxo-1-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]pyrimidin-5-yl]-N,N-dimethylethanethioamide

(S)-1-[4-[[2-(2-Aminopyrimidin-5-yl)-7-methyl-4-(morpholin-4-yl)thieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one;GNE 390;GDC-0980;(S)-1-(4-((2-(2-aMinopyriMidin-5-yl)-7-Methyl-4-Morpholinothieno[3,2-d]pyriMidin-6-yl)Methyl)piperazin-1-yl)-2-hydroxypropan-1-one;GDC-0980 (RG7422);Apitolisib;Apitolisib (GDC-0980, RG7422);(S)-1-[4-[[2-(2-Aminopyrimidin-5-yl)-7-methyl-4-(morpholin-4-yl)thieno[3,2-d]pyrimidin-6-yl]methyl]piperazin-1-yl]-2-hydroxypropan-1-one GNE 390GDC0980(RG7422)

GSK1904529A;GSK1904529A : IGF-IR, IGF-IIR inhibitor;N-(2,6-Difluorophenyl)-5-[3-[2-[[5-ethyl-2-(methyloxy)-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-2-(methyloxy)benzamide;GSK 4529;N-(2,6-difluorophenyl)-5-(3-(2-(5-ethyl-2-methoxy-4-(4-(4-(methylsulfonyl)piperazin-1-yl)piperidin-1-yl)phenylamino)pyrimidin-4-yl)H-imidazo[1,2-a]pyridin-2-yl)-2-methoxybenzamide;N-(2,6-Difluorophenyl)-5-[3-[2-[[5-ethyl-2-(methyloxy)-4-[4-[4-(methylsulfonyl)-1-piperazinyl]-1-piperidinyl]phenyl]amino]-4-pyrimidinyl]imidazo[1,2-a]pyridin-2-yl]-2-(methyloxy)benzamide GSK 1904529A;GSK1904529A, >=98%;IGF-IR, IGF-IIR inhibitor

Quinoline,4-[6-[4-(1-piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]-;4-[6-[4-(1-Piperazinyl)phenyl]pyrazolo[1,5-a]pyrimidin-3-yl]quinoline;LDN 193189;DM 3189

1H-Pyrrole-2,5-dione,3-(1-methyl-1H-indol-3-yl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-1H-indol-3-yl]-;3-(1-Methyl-1H-indol-3-yl)-4-[1-[1-(2-pyridinylmethyl)-4-piperidinyl]-1H-indol-3-yl]-1H-pyrrole-2,5-dione;Enzastaurin;3-(1-Methyl-1H-indol-3-yl)-4-[1-[1-[(pyridin-2-yl)methyl]piperidin-4-yl]-1H-indol-3-yl]pyrrole-2,5-dione;3-(1-Methylindol-3-yl)-4-[1-[1-(pyridin-2-ylmethyl)piperidin-4-yl]indol-3-yl]pyrrole-2,5-dione;DB 102

1-Piperazineacetic acid,4-(phenylmethyl)-,2-[[2-hydroxy-3-(2-propen-1-yl)phenyl]methylene]hydrazide;1-Piperazineacetic acid,4-(phenylmethyl)-,[[2-hydroxy-3-(2-propenyl)phenyl]methylene]hydrazide;Procaspase activating compound 1;PAC 1

2-Butenamide,N-[4-[(3-chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-,(2E)-;(2E)-N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-quinazolinyl]-4-(1-piperidinyl)-2-butenamide;Dacomitinib;PF 00299804;PF 299804;PF 299;1006885-28-4

Cyclohexaneacetamide,α-amino-N-[5,6-dihydro-2-(1-methyl-1H-pyrazol-4-yl)-6-oxo-1H-pyrrolo[4,3,2-ef][2,3]benzodiazepin-8-yl]-,(αR)-;(αR)-α-Amino-N-[5,6-dihydro-2-(1-methyl-1H-pyrazol-4-yl)-6-oxo-1H-pyrrolo[4,3,2-ef][2,3]benzodiazepin-8-yl]cyclohexaneacetamide;PF 477736;PF 00477736;1071848-28-6

Benzamide,3-[3-bromo-4-[(2,4-difluorophenyl)methoxy]-6-methyl-2-oxo-1(2H)-pyridinyl]-N,4-dimethyl-;3-[3-Bromo-4-[(2,4-difluorophenyl)methoxy]-6-methyl-2-oxo-1(2H)-pyridinyl]-N,4-dimethylbenzamide;3-Bromo-4-[(2,4-difluorobenzyl)oxy]-1-[5-[(methylamino)carbonyl]-2-methylphenyl]-6-methylpyridin-2(1H)-one;PH 797804;1073667-47-6

Spiro[2H-indole-2,3′-[3H]naphth[2,1-b][1,4]oxazine],1,3-dihydro-1,3,3-trimethyl-;Spiro[indoline-2,3′-[3H]naphth[2,1-b][1,4]oxazine],1,3,3-trimethyl-;1,3-Dihydro-1,3,3-trimethylspiro[2H-indole-2,3′-[3H]naphth[2,1-b][1,4]oxazine];1,3,3-Trimethylspiro[indoline-2,3′-[3H]naphth[2,1-b][1,4]oxazine];Variacrol Blue A;Photorom I;Photorome I;1,3-Dihydro-1,3,3-trimethylspiro[2H-indole-2,3′-[3H]naphth[2,1-h][1,4]oxazine];T 1259;1,3,3-Trimethylindolinonaphthospirooxazine;1,3,3-Trimethylindolinospironaphthooxazine;1,3,3-Trimethylindolinonaphthospiroxazine;Photopia AQ Ink Blue;1′,3′,3′-Trimethylspiro[benzo[f][1,4]benzoxazine-3,2′-indole];1,3,3-Trimethyl-1,3-dihydrospiro[indole-2,3′-naphtho[2,1-b][1,4]oxazine];120026-33-7;138780-10-6;199195-44-3;960373-06-2;1225595-26-5